



**INDEPENDENT AUDITOR'S REPORT**

To,  
The Members  
Governing Council of  
M/s. Institute for Stem Cell Science and Regenerative Medicine  
Bangalore-560065

**Report on the Audit of the standalone Financial Statements**

**Opinion**

We have audited the financial statements of "Institute for Stem Cell Science and Regenerative Medicine", which comprises the Balance Sheet as at 31st March 2024, the Income and Expenditure Account and Receipts and Payments account for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion and to the best of our information and according to the explanations given to us, the accompanying financial statements give a true and fair view of the financial position of the Institute as at 31st March 2024, of its financial performance and Receipts and Payments for the year ended in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India (ICAI).

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) issued by ICAI. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the entity in accordance with the Code of Ethics issued by ICAI and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



## **Other Matters**

We have not audited the financial statements of CSCR at Vellore, whose financial statements reflect total assets of Rs. 16.89 crores, total revenue of Rs.10.85 crores and excess of income over expenditure of Rs. 2.10 crores for the year ended as on 31-03-2024. These financial statements have been audited by other auditor whose reports have been furnished to us by the Management.

## **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation of the financial statements in accordance with generally accepted accounting principles in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the entity's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for



one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

†

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For T. Ramachandran & Co.**

Chartered Accountants

Firm Registration Number: 009009S

**T. Ramachandran**

Partner

Membership No.: 207600

Date: 17.08.2024

Place: Bangalore

UDIN: 24207600BJZWLV6800



GFR 12 - A (See Rule 238(1))  
**FORM OF UTILISATION CERTIFICATE FOR AUTONOMOUS BODIES OF THE GRANTEE ORGANSATION**  
 AUDITED UTILISATION FOR THE YEAR 2023-24 in respect of recurring/non recurring  
 GRANTS-IN-AID/SALARIES/CREATION OF CAPITAL ASSETS

1. Name of the Scheme : Institute for Stem Cell Science and Regenerative Medicine
2. Whether recurring or no recurring grants
3. Grants position at the beginning of the Financial year  
 (i) Cash in Hand/Bank (9,74,55,128.00)  
 (ii) Unadjusted advances  
 (iii) Total (9,74,55,128.00)

4. Details of grants received expenditure incurred and closing balances:(Actuals)

Unspent Balances of grants received years (Figure as at Sl. no 3(iii))	Interest earned thereon	Unspent Balance/ Interest deposited back to the Govt.	Grant received during the year			Total available Fund (1+2-3+4)	Expenditure incurrerd	Closing Balances (5-6)
			Sanction No. (i)	Date (ii)	Amount (iii)			
(9,74,55,128.00)	21,38,925.00	4,55,192.00	No. AID-19015/1/2020-MED-DBT	25.04.2023	9,00,00,000.00	56,65,28,605	59,73,58,184	(3,08,29,579)
			No. AID-19015/1/2020-MED-DBT	25.04.2023	16,00,00,000.00			
			No. AID-19015/1/2020-MED-DBT	25.04.2023	8,50,00,000.00			
			No. AID-19015/1/2020-MED-DBT	05.12.2023	4,50,00,000.00			
			No. AID-19015/1/2020-MED-DBT	05.12.2023	8,00,00,000.00			
			No. AID-19015/1/2020-MED-DBT	05.12.2023	4,25,00,000.00			
			No. AID-19015/1/2020-MED-DBT	01.03.2024	5,25,00,000.00			
			No. AID-19015/1/2020-MED-DBT	01.03.2024	7,00,00,000.00			
			No. AID-19015/1/2020-MED-DBT	01.03.2024	1,50,00,000.00			
			No. AID-19015/1/2020-MED-DBT	22.03.2024	2,23,00,000.00			
					66,23,00,000.00			

Component wise utilisation of grants

Grant in aid General	Grant in Aid -Salary	Grant in aid-creation of capital assets	Total
30,87,42,963	16,28,12,236	12,58,02,985	59,73,58,184

- Details of Grant position at the end of the year  
 (i) Cash in Hand/Bank (3,08,29,579)  
 (ii) Unadjusted advances  
 (iii) Total (3,08,29,579)


Certified that I have satisfied myself that the conditions on which grants were sanctioned have been duly fulfilled/are being fulfilled and that I have exercised following checks to see that the money has been actually utilized for the purpose for which it was sanctioned:


- (i) The main accounts and the other subsidiary accounts and registers (including assets registers) are maintained as prescribed in the relevant Act/Rules/Standing instructions (mentioned the Act/Rules) and have been duly audited by designated auditors. The figures depicted above tally with the audited figures mentioned in financial statements/accounts.
- (ii) There exist internal controls for safeguarding public funds/assets watching outcomes and achievements of physical targets against the financial inputs insuring quality in asset creation etc. & the periodic evaluation of internal controls is exercised to ensure their effectiveness.
- (iii) To the best of our knowledge and belief no transactions have been entered that are in violation of relevant Act/Rules/Standing instructions and scheme guidelines agreements (Tripartite Agreement) sanction letters contract agreements/LoAs/amendments in LoAs and agreements.
- (iv)The responsibilities among the key functionaries for execution of the scheme have been assigned in clear terms and are not general in nature.
- (v) The benefits were extended to the intended beneficiaries and only such areas/districts were covered where the scheme was intended to operate.
- (vi) The expenditure on various components of the scheme was in proportions authorized as per the scheme guidelines and terms and conditions of the grants-in-aid.


- (vii) It has been ensured that the physical and financial performance under IPDS has been according to the requirements as prescribed in the guidelines issued by Govt. of India and the (viii) The utilization of the fund resulted in outcomes given at Annexure-II duly enclosed (to be formulated by the Ministry/Department concerned as per their requirements/specifications).


(ix) Details of unutilized grants sanctioned by the agency through grants-in-aid received from the same Ministry or from other Ministries is enclosed at Annexure-II (to be formulated by the Ministry/Department concerned as per their requirements/specifications).


- Note: (1) Interest amount of Rs.21,36,132/- pertaining to inStem for the FY 2023-24 is refunded on 08-08-2024 to CFI vide Bharatkosh Receipt No.0708240032082.  
 (2) Interest amount of Rs.2,793/- pertaining to CSCR for the FY 2023-24 is refunded on 13-05-2024 to CFI vide Bharatkosh Receipt No.1305240019863.  
 (3) CFI- General Opening Balance of inStem amounting to Rs.4,55,192/- for FY 2023-24 is refunded on 04-10-2023 to CFI vide Bharatkosh Receipt No.0410230010218.

(T. RAMACHANDRAN) Partner  
 Membership No. 207600  
  
 (T Ramachandran) Partner  
 Administrative Officer (Finance & Accounts)  
 Place: Bangalore  
 Date : 17.8.2024

  
 Madhu Chandan Roy  
 Administrative Officer - F & A

  
 (Ramanathan. K)  
 Sr. Administrative Officer

  
 (A. K. Prakash)  
 Registrar

  
 (Prof. Maneesha S. Inamdar)  
 Director

मधु चंदन राय / Madhu Chandan Roy  
 प्रशासनिक अधिकारी (वित्त एवं खाते)  
 Senior Administrative Officer  
 Institute for Stem Cell Science and Regenerative Medicine (inStem)  
 (AI under Department of Biotechnology, MoST, Govt. of India)  
 GKVK Post, Bellary Road, Bengaluru - 560 065

कुलसचिव / Registrar  
 ए.के. प्रकाश / A K Prakash  
 (An Autonomous Institute under Department of Biotechnology, MoST, Govt. of India)  
 GKVK Post, Bellary Road, Bengaluru - 560 065

प्रो. मनीषा एस इनमदार / Prof. Maneesha S Inamdar  
 निदेशक / Director  
 पुनर्व्यंजी औषधी संस्थान (डीबीटी-इंस्टे)  
 Institute for Stem Cell Science and Regenerative Medicine (DBT - inStem)  
 प्रौद्योगिकी विभाग, विज्ञान एवं प्रौद्योगिकी मंत्रालय, भारत सरकार के अधीन एक स्वायत्त संस्थान  
 (AI under Department of Biotechnology, MoST, Govt. of India)  
 जीकेवीके पोस्ट, बेल्लारी रोड, बेंगलुरु-५६० ०६५  
 GKVK Post, Bellary Road, Bengaluru- 560 065

UDIN : 2102076002TW11X7952



**INSTITUTE FOR STEM CELL SCIENCE & REGENERATIVE MEDICINE, BANGALORE**

**AUDITED STATEMENT OF EXPENDITURE FOR THE PERIOD FROM 01.04.2023 TO 31.03.2024**

Sl.No.	Particulars	Unspent balance as on 01.04.2023 as per Audited SOE & UC	Grants received from DBT during the period 01.04.2023 to 31.03.2024	Other receipts/interest earned on the DBT Grants	Total	Expenditure incurred (excluding commitments) from 01.4.2023 to 31.3.2024	Interest or Unspent amount Refunded/Amount Lapsed in TSA	Balance as on 31.03.2024
1	2	3	4	5	6=3+4+5	7	8	9=6-7-8
	<b>INSTEM :</b>							
A	GIA - Capital							
(i)	Equipments & Accessories	-2,43,00,316	10,14,00,000	-	7,70,99,684	7,72,04,489	-	-1,04,805
	<b>Total (A)</b>	<b>-2,43,00,316</b>	<b>10,14,00,000</b>	<b>-</b>	<b>7,70,99,684</b>	<b>7,72,04,489</b>	<b>-</b>	<b>-1,04,805</b>
B	GIA - Salary							
(ii)	Manpower	-5,11,41,713	14,85,00,000	-	9,73,58,287	12,50,28,299	-	-2,76,70,012
	<b>Total (B)</b>	<b>-5,11,41,713</b>	<b>14,85,00,000</b>	<b>-</b>	<b>9,73,58,287</b>	<b>12,50,28,299</b>	<b>-</b>	<b>-2,76,70,012</b>
C	GIA - General							
(iii)	Recurring Expenses	4,55,192	25,52,65,000	-	25,57,20,192	26,04,58,687	4,55,192	-51,93,687
	<b>Total (C)</b>	<b>4,55,192</b>	<b>25,52,65,000</b>	<b>-</b>	<b>25,57,20,192</b>	<b>26,04,58,687</b>	<b>4,55,192</b>	<b>-51,93,687</b>
D	Other receipts							
E	Interest Earned			21,36,132	21,36,132			21,36,132
F	Interest Refunded							
	<b>GRAND TOTAL (A+B+C+D+E+F) - INSTEM</b>	<b>-7,49,86,837</b>	<b>50,51,65,000</b>	<b>21,36,132</b>	<b>43,23,14,295</b>	<b>46,26,91,475</b>	<b>4,55,192</b>	<b>-3,08,32,372</b>
	<b>CSCR Vellore :</b>							
G	GIA - Capital	-1,504	4,86,00,000		4,85,98,496	4,85,98,496		
H	GIA - Salary	-1,60,16,063	5,38,00,000		3,77,83,937	3,77,83,937		
I	GIA - General	-64,50,724	5,47,35,000		4,82,84,276	4,82,84,276		
J	Interest Earned			2,793	2,793			2,793
K	Interest Refunded							
	<b>GRAND TOTAL (G+H+I+J+K) - CSCR</b>	<b>-2,24,68,291</b>	<b>15,71,35,000</b>	<b>2,793</b>	<b>13,46,69,502</b>	<b>13,46,66,709</b>	<b>-</b>	<b>2,793</b>
	<b>GRAND TOTAL - INSTEM + CSCR</b>	<b>-9,74,55,128</b>	<b>66,23,00,000</b>	<b>21,38,925</b>	<b>56,69,83,797</b>	<b>59,73,58,184</b>	<b>4,55,192</b>	<b>-3,08,29,579</b>

Note: (1) Interest amount of Rs.21,36,132/- pertaining to inStem for the FY 2023-24 is refunded on 08-08-2024 to CFI vide BharatKosh Receipt No.0708240032082.

(2) Interest amount of Rs.2,793/- pertaining to CSCR for the FY 2023-24 is refunded on 13-05-2024 to CFI vide BharatKosh Receipt No.1305240019863.

(3) GIA-General Opening Balance of inStem amounting to Rs.4,55,192/- for FY 2023-24 is refunded on 04-10-2023 to CFI vide BharatKosh Receipt No.0410230010218.

**(T Ramachandram)**  
Partner (M.No.207600)/7600  
Place: Bangalore  
Date : 17.08.2024

**(Madhu Chandan Roy)**  
Admin Officer (F&A)

**Ramanathan K**  
Sr.Admin Officer

**ए.के. (AK)Prakash**  
Registrar

**(Prof. Maneesha Inamdar)**  
Director

**मधु चन्दन राय / Madhu Chandan Roy**  
प्रशासनिक अधिकारी (वित्त एवं लेखा)  
Administrative Officer (Finance & Accounts)  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्थन एवं अर्थन अख्य, गैंगलूरु-५६० ०६५ / GKVK Post, Bellary Road, Bengaluru-560 065

**Ramanathan K**  
Senior Administrative Officer  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्थन एवं अर्थन अख्य, गैंगलूरु-५६० ०६५ / GKVK Post, Bellary Road, Bengaluru-560 065

**ए.के. (AK)Prakash**  
Registrar  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्थन एवं अर्थन अख्य, गैंगलूरु-५६० ०६५ / GKVK Post, Bellary Road, Bengaluru-560 065

**(Prof. Maneesha Inamdar)**  
Director  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्थन एवं अर्थन अख्य, गैंगलूरु-५६० ०६५ / GKVK Post, Bellary Road, Bengaluru-560 065

INSTITUTE FOR STEM CELL SCIENCE & REGENERATIVE MEDICINE, BANGALORE

(Registered under the Karnataka Societies' Registration Act)

GKVK, BELLARY ROAD, BANGALORE - 560 065

RECEIPTS AND PAYMENTS STATEMENT FOR THE YEAR ENDED MARCH 31, 2024

RECEIPTS	CY 2023-24	PY 2022-23	PAYMENTS	CY 2023-24	PY 2022-23
<b>I. Opening Balances</b>					
a) Cash in hand	24	24			
b) Bank Balances					
i) in current accounts	90,21,512	59,00,638			
ii) in deposit accounts	3,05,97,889	16,30,11,390			
iii) in savings accounts	12,04,67,505	18,26,24,829			
<b>II. Grants Received</b>	<b>16,00,86,930</b>	<b>35,15,36,881</b>			
a) From Govt. of India	66,23,00,000	49,78,69,530			
b) From State Govt.	-	-			
<b>III. Project Receipts-Projects</b>	<b>66,23,00,000</b>	<b>49,78,69,530</b>			
<b>IV. Decrease in Current Assets</b>	<b>37,00,72,374</b>	<b>16,22,92,882</b>			
<b>V. Interest Received</b>		<b>56,35,483</b>			
a) On Bank deposits	1,07,34,006	71,48,057			
b) on Loans, Advances etc.					
<b>VI. Other Income (Specify)</b>	<b>1,07,34,006</b>	<b>71,48,057</b>			
<b>VII. Amount Borrowed</b>	<b>3,40,94,932</b>	<b>2,05,06,927</b>			
<b>VIII. Any other receipts</b>					
<b>IX. Increase in Current Liabilities</b>					
<b>TOTAL</b>	<b>1,23,72,88,242</b>	<b>1,04,49,89,760.00</b>	<b>TOTAL</b>	<b>1,23,72,88,242</b>	<b>1,04,49,89,760</b>

Vide our report of even date

For T Ramachandran & Co Chandran & Co

Chartered Accountants

(T Ramachandran)  
Partner (M.No.207600)  
BANGALORE

Place: Bangalore

Date : 17.08.2024

(Madhu Chandan Roy)  
Admin Officer (F&A)  
Ramanathan K

**Rafiqul Karim**  
Rafiqul Karim  
Rafiqul Karim

**E. K. Prakash**  
E. K. Prakash  
E. K. Prakash

**Prof. Maneesha S Inamdar**  
Prof. Maneesha S Inamdar  
Prof. Maneesha S Inamdar

Prशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

प्रशासक अधिकारी (वित्त एवं लेखा)

**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**

(Registered under the Karnataka Societies' Registration Act.)


GKVK, BELLARY ROAD, BANGALORE - 560 065

**BALANCE SHEET AS AT MARCH 31, 2024**

		(Amount- Rs.)	
Particulars	Schedule	CY 2023-24	PY 2022-23
<b>CORPUS/CAPITAL FUND AND LIABILITIES</b>			
CORPUS/CAPITAL FUND	1	12,83,53,021	2,07,58,788
RESERVES AND SURPLUS	2	2,22,57,01,940	2,36,59,84,315
EARMARKED/ ENDOWMENT FUNDS	3	24,89,32,285	14,82,33,552
SECURED LOANS AND BORROWINGS	4	-	-
UNSECURED LOANS AND BORROWINGS	5	-	-
DEFERRED CREDIT LIABILITIES	6	-	-
CURRENT LIABILITIES AND PROVISIONS	7	5,31,39,895	7,43,14,825
<b>ASSETS</b>		<b>2,65,61,27,141</b>	<b>2,60,92,91,480</b>
FIXED ASSETS	8	2,27,28,25,856	2,41,31,08,230
INVESTMENTS - FROM EARMARKED /ENDOWMENT FUNDS	9	-	-
INVESTMENTS - OTHERS	10	600	600
CURRENT ASSETS, LOANS, ADVANCES ETC.	11	38,33,00,685	19,61,82,650
<b>TOTAL</b>		<b>2,65,61,27,141</b>	<b>2,60,92,91,480</b>
<b>SIGNIFICANT ACCOUNTING POLICIES</b>	24		
<b>CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS</b>	25		

Vide our report of even date

For T Ramachandran & Co  
Chartered Accountants



(T Ramachandran)  
Partner (M.No.207600)

(Madhu Chandan Roy)  
Admin Officer (F&A)

मधु चन्दन राय / Madhu Chandan Roy  
प्रशासनिक अधिकारी (वित्त एवं लेखा)  
Administrative Officer (Finance & Accounts)  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्धन स्वतंत्र संस्थान (AI) under Department of Biotechnology, Govt. of India

Place: Bangalore  
Date : 17.08.2024

*(Signature)*

(AK Prakash)  
ए.के. Registrar  
क़ुलसचिव / Registrar

(Prof. Maneesha Inamdar)  
प्रो. मनीषा एस इनमदर / Prof. Maneesha S Inamdar  
निदेशक / Director

सेम कोशिका विज्ञान एवं पुनर्जाती औषधी संस्थान (इंजीडी-इंस्टेम)  
Institute for Stem Cell Science and Regenerative Medicine (inStem)  
जैव प्रौद्योगिकी विभाग, भारत सरकार के अर्धन स्वतंत्र संस्थान (AI) under Department of Biotechnology, MoST, Govt. of India  
भारत सरकार के अर्धन स्वतंत्र संस्थान  
Institute under Department of Biotechnology, MoST, Govt. of India  
जीकेवीके पोस्ट, बेल्लारी रोड, बंगलुरु-560 065.  
GKVK Post, Bellary Road, Bengaluru- 560 065.

INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE

(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED MARCH 31, 2024

(Amount- Rs.)

Particulars	Schedule	CY 2023-24	PY 2022-23
<b>INCOME</b>			
Income from Projects - to the extent of expenditure included	3	17,27,23,704	16,34,06,279
Income from Sales and Services	12	2,60,52,807	1,08,72,378
Grants/Subsidies	13	51,23,00,000	34,41,32,896
Fees/Subscriptions	14	-	-
Income from Investments	15	-	-
Income from Royalty, Publications etc.	16	-	-
Interest earned	17	23,85,642	18,45,775
Other Income	18	80,42,125	96,34,549
Increase/(decrease) in stock of Finished goods and works-in-progress	19	-	-
<b>TOTAL (A)</b>		<b>72,15,04,278</b>	<b>52,98,91,877</b>
<b>EXPENDITURE</b>			
Establishment Expenses	20	16,70,04,376	14,18,16,876
Other Administrative Expenses	21	30,69,67,609	26,25,75,884
Expenditure on Grants/Subsidies etc.	22	17,27,23,704	16,34,06,279
Interest	23	5,81,934	8,23,409
Depreciation (Net Total at the year -end -corresponding to Sch.8)		28,73,43,683	30,93,00,483
<b>TOTAL (B)</b>		<b>93,46,21,306</b>	<b>87,79,22,932</b>
<b>Balance being excess of Expenditure over Income (A-B)</b>		<b>-21,31,17,028</b>	<b>-34,80,31,055</b>
Less- Transfer from Capital Reserve - equivalent to depreciation charges	2(1)	28,73,43,683	30,93,00,483
Less- Transfer to/from General Reserve - Recurring Grant Account	1(B)	7,42,26,655	-3,87,30,571
Balance being surplus/deficit carried to Corpus/Capital Fund		-	-

Vide our report of even date  
For T Ramachandran & Co  
Chartered Accountants



(T Ramachandran)  
Partner (M.No.207600)

Place: Bangalore  
Date : 17.08.2024

(Madhu Chandan Roy)  
Admin Officer (F&A)

(Ramanathan K)  
Sr.Admin Officer

मधु चवन राय / Madhu Chandan Roy  
प्रशासनिक अधिकारी (वित्त एवं लेखा) / Institute for Stem Cell Science and Regenerative Medicine (inStem)  
Adminstrative Officer (Finance & Accounts) / Institute for Stem Cell Science and Regenerative Medicine (inStem)  
स्टेम कोशिका विज्ञान और पुनर्प्राप्ति संस्थान / GKVK Campus, Bellary Road, Bengaluru-560065, भारत सरकार के अधीन एक स्वायत्त संस्थान  
(AI) under Department of Biotechnology, Govt. of India

(A.K.Prakash)  
Registrar

(Prof. Maneesha Inamdar)  
Director

ए.के.प्रकाश / A.K.Prakash  
बुलसाचिव / Registrar  
मूल कोशिका विज्ञान एवं पुनर्प्राप्ति संस्थान (आयसीएसआर) / Institute for Stem Cell Science and Regenerative Medicine (inStem)  
स्टेम कोशिका विज्ञान एवं पुनर्प्राप्ति संस्थान (आयसीएसआर) / Institute for Stem Cell Science and Regenerative Medicine (inStem)  
बैंगलूरु-560 005, बेल्लारी रोड, बेल्गूरु-560 065, भारत सरकार के अधीन एक स्वायत्त संस्थान  
(AI) under Department of Biotechnology, MOST, GOVT. OF INDIA  
जीकेवीके पोस्ट, बेल्लारी रोड, बेल्गूरु-560 065, भारत सरकार के अधीन एक स्वायत्त संस्थान  
(AI) under Department of Biotechnology, MOST, GOVT. OF INDIA



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
(Registered under the Karnataka Societies' Registration Act.)


GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

	[Amount- Rs.]	
	CY 2023-24	PY 2022-23
<b>SCHEDULE-1 - CORPUS/CAPITAL FUND:</b>		
<b>(A) NON-RECURRING GRANT</b>		
Balance at the beginning of the year	4,57,74,803	12,88,04,727
Add: Contributions during the year	15,00,00,000	15,37,36,634
Less: Expenditure incurred during the year	11,26,79,700	18,11,82,399
Adjustments, if any *	-	-5,55,84,159
<b>BALANCE AS AT THE YEAR END (A)</b>	<b>8,30,95,103</b>	<b>4,57,74,803</b>
<b>(B) RECURRING GRANT</b>		
Balance as at the beginning of the year	-2,50,16,015	1,52,50,040
Grants returned to DBT *	-4,55,192	-15,35,484
Adjustment pertaining to previous years	-34,97,530	-
Transferred from Income & Expenditure	7,42,26,655	-3,87,30,571
<b>BALANCE AS AT THE YEAR END (B)</b>	<b>4,52,57,918</b>	<b>-2,50,16,015</b>
<b>TOTAL (A) + (B)</b>	<b>12,83,53,021</b>	<b>2,07,58,788</b>

\* Note: Unspent balance under non-recurring of inStem for FY 2021-22 amounting to rs.1,08,53,579/- was returned in FY 2022-23 to Consolidated fund of India through Bhartkosh Transaction No. 0904220002038. Inadvertently, in FY 2022-23 under Schedule-1 the same was shown under Recurring Grant (1B) instead of non-recurring grant (1A), which is now appropriately adjusted in the Previous Year figures and respective balances are carried to Current year. Due to this there is no change in the Financial Statements.

	[Amount- Rs.]	
	CY 2023-24	PY 2022-23
<b>SCHEDULE-2 - RESERVES AND SURPLUS:</b>		
<b>1: CAPITAL RESERVE</b>		
As per last account	2,36,59,84,315	2,48,66,66,494
Add: Adjustments of previous years	-223	-
Addition during the year - Capital addition	14,70,61,532	18,86,18,304
Less: Deduction during the year - Depreciation	28,73,43,683	30,93,00,483
<b>TOTAL</b>	<b>2,22,57,01,940</b>	<b>2,36,59,84,315</b>
<b>2: REVALUATION RESERVE:</b>	-	-
<b>3: SPECIAL RESERVES:</b>	-	-
<b>4: GENERAL RESERVE:</b>	-	-
<b>Total Reserves &amp; Surplus</b>	<b>2,22,57,01,940</b>	<b>2,36,59,84,315</b>



SCHEDULE -3-EARMARKED / ENDOWMENT FUNDS

Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure		Adjustment	Total Expenditure	Balance as on 31-03-2024
									Capital	Revenue			
1	From Government												
1	DBT JRF (8138-Oindrilla Bamerjee)	8138	DBT	15,862	-	-	-	-	-	-	-	-	15,862
2	Mahendra Rao (8146)	8146	DBT	18,50,159	24,645	-	-	-	-	-	-	-	18,74,804
3	DBTBA Fellowship (8149-Bhakti Vyas)	8149	DBT	1,02,000	-	-	-	-	-	-	-	-	1,02,000
4	DBTBA Fellowship (8153-Mohd M)	8153	DBT	1,04,028	-	-	-	-	-	-	-	-	1,04,028
5	ICMR Fellowship (8155-Radhika Rao)	8155	ICMR	27,208	-	-	-	-	-	-	-	-	27,208
6	ICMR Fellowship (8158-Edries Y H)	8158	ICMR	2,07,265	-	-	-	-	-	-	-	-	2,07,265
7	ICMR Fellowship (8159-Isha Rana)	8159	ICMR	22,400	-	-	-	-	-	-	-	-	22,400
8	CSIR Fellowship (8162-Abhinava Yadav)	8162	CSIR	15,068	-	-	-	-	-	-	-	-	15,068
9	CSIR Fellowship (8164-Lakshmi Kripa)	8164	CSIR	20,000	-	-	-	-	-	-	-	-	20,000
10	CSIR Fellowship (8166-Lakshmi Gulami)	8166	CSIR	34,998	-	-	-	-	-	-	-	-	34,998
11	DBT BA Fellowship (8167-Anupam Dutt)	8167	DBT	13,048	-	-	-	-	-	-	-	-	13,048
12	DBT BA Fellowship (8168-Anusree Mahanta)	8168	DBT	66,567	-	-	-	-	-	-	-	-	66,567
13	DBT JRF Fellowship (8173-Harshadri)	8173	DBT	9,166	-	-	-	-	-	-	-	-	9,166
14	DBT JRF Fellowship (8178-Uttkarsh I)	8178	DBT	60,000	-	-	-	-	-	-	-	-	60,000
15	DBT JRF Fellowship (8179-Sonal Joshi)	8179	DBT	20,000	-	-	-	-	-	-	-	-	20,000
16	DBT JRF Fellowship (8180-Vishwaja Javeri)	8180	DBT	1,68,760	-	-	-	-	-	-	-	-	1,68,760
17	DST Inspire Fellowship (8181- Manisha Goyal)	8181	DST - Inspire	-	7,05,560	-	-	-	-	-	-	-	7,05,560
18	DBT SHF Fellowship (8182-Pratul Jain)	8182	DBT	42,520	-	-	-	-	-	-	-	-	42,520
19	DST Inspire Fellowship (8184- Michelle Dsouza)	8184	DST - Inspire	15,000	5,70,520	-	-	-	-	-	-	-	5,85,520
20	DST Inspire Fellowship (8185-Sreeta Sreedharan)	8185	DST - Inspire	-	7,38,799	-	-	-	-	-	-	-	7,38,799
21	DBT BA Fellowship (8188-Gaurav Singh)	8188	DBT	1,62,836	5,71,840	-	-	-	-	-	-	-	7,34,676
22	ICMR Fellowship (8189-Pratul Jain)	8189	ICMR	21,725	5,08,950	-	-	-	-	-	-	-	5,30,675
23	ICMR Fellowship (8190- Vinay J Rao)	8190	ICMR	21,401	5,53,400	-	-	-	-	-	-	-	5,74,801
24	DBT JRF Fellowship (8191-Radhika Agrawal)	8191	RCB-DBT	31,290	4,91,280	-	-	-	-	-	-	-	5,22,570
25	DBT JRF Fellowship (8192-Ravi Kiran)	8192	RCB-DBT	47,809	6,02,880	-	-	-	-	-	-	-	6,50,689
26	SERB Postdoc University Overseas Visiting Doctoral Fellowship	8193	SERB	4,86,000	-	-	-	-	-	-	-	-	4,86,000
27	CSIR Contingency received to Sreenath R. (8127)	8127	CSIR	1,176	1,99,200	-	-	-	-	-	-	-	2,00,376
28	Sumana Ghosh (8186)	8186	CSIR	39,758	-	-	-	-	-	-	-	-	39,758
29	DBT JRF Fellowship (8194- Aswini Venkateshwaran)	8194	DBT	27,419	6,02,880	-	-	-	-	-	-	-	6,30,299
30	DBT JRF Fellowship (8195- Sneha Muralidharan)	8195	DBT	50,000	2,08,320	-	-	-	-	-	-	-	2,58,320
31	DBT JRF Fellowship (8196- Diksha Gogia)	8196	DBT	65,604	6,02,880	-	-	-	-	-	-	-	6,68,484
32	DST Inspire Fellowship (8197- Saraswati Sanjay Chavda)	8197	DST - Inspire	-	1,25,195	-	-	-	-	-	-	-	1,25,195
33	DBT JRF Fellowship (8198- Sahana Vasudevan)	8198	DBT	8,333	6,95,320	-	-	-	-	-	-	-	7,03,653
34	DBT JRF Fellowship (8199- Debansha Prithwanjari Panigrahi)	8199	DBT	8,333	6,24,467	-	-	-	-	-	-	-	6,32,800
35	DBT JRF Fellowship (8200- Susobhan Mahantny)	8200	DBT	8,333	6,24,467	-	-	-	-	-	-	-	6,32,800
36	DBT JRF Fellowship (8201- Sanjana Mullick)	8201	DBT	-	5,74,129	-	-	-	-	-	-	-	5,74,129
37	DBT JRF Fellowship (8202- Jagruti Arora)	8202	DBT	-	3,16,082	-	-	-	-	-	-	-	3,16,082
38	DBT JRF Fellowship (8203- Sucheta Devi)	8203	DBT	-	3,16,000	-	-	-	-	-	-	-	3,16,000
39	Other Miscellaneous Grant	0001	-	82,979	-	-	-	-	-	-	-	-	82,979
40	Novel Cell Surface Markers for endodermal stem and progenitor cells in health and disease (8214) & CSIR	8214	DBT	3,70,118	-	-	-	-	-	-	-	-	3,70,118
41	Therapeutic approaches to augmentation of Adult cardiac stem cells (8217- Prof. Jyotsna Dhawan)	8217	DBT	7,54,889	-	-	-	-	-	-	-	-	7,54,889
42	DBT Twinning Programme for the North East - Molecular Mechanism of target recognition and cleavage by the CRISPR-CAS bacterial immune system (8220-Prof. Ramaswamy)	8220	DBT	3,88,853	-	-	-	-	-	-	-	-	3,88,853
43	Muscle SC self renewal: A stressful matter (8225- CEFIPRA Grant- Prof. Jyotsna Dhawan)	8225	CEFIPRA	1,87,054	-	-	-	-	-	-	-	-	1,87,054
44	Molecular mechanisms that regulate cyto skeletal modelling in cardiac hypertrophy by developing an in-vitro human cardiomyocyte culture microfluidic system ( 8229 - Prof. Jyotsna Dhawan)	8229	DST	4,51,756	0	-	-	-	-	-	-	-	4,51,756
45	Imaging synaptic plasticity in control: Novel protein carbon nanotube fluorescent sensors for regulation of protein translation- (8239 Dr. Aksh Gulavani)	8239	DBT	5,36,842	-	-	-	-	-	-	-	-	5,36,842
46	Structure-Function studies on nucleotide sugar transporters Indo Arunima program (8249 prof Ramaswamy)	8249	DST	-43,335	-	-	-	-	-	-	-	-	-43,335
47	Accelerating the application of stemcell technology in human disease (AS40-8251 Prof. Anuska Dr. Basu Padigoti)	8251	DBT	3,59,473	2,32,37,020	2,35,42,668	-	-	-	-	-	-	3,31,265
48	Mining the Genome and Metagenome of Marine Microbiome for PKS-NRPS Biosynthetic Gene Cluster and Bioactive Small Molecules : A coordinated R & D Initiative in marine Genomics (8257-Dr. Praveen Kumar Vemula)	8257	DBT	1,74,294	-	-	-	-	-	-	-	-	1,74,294



Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Return during the year	Interest received	Interest Returned	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2024
49	Ranalingeswamy Grant (8258-Tina Mukherjee)	8258	DBT	2,50,309	-	-	-	-	-	-	-	-	2,50,309
50	Neurostem: Stem cell Models for Discovery of RNA-Mediated Regulation in Neurodegeneration (8260-Dr. Ravi Muddashty)	8260	DBT	-3,96,121	-	-	-	-	-	-	-	-	-3,96,121
51	Genetic Program Controlling Mesoderm Differentiation (8272-Ramakrishna Sambasivan)	8272	DBT	1,84,669	-	-	-	-	-	-	-	-	1,84,669
52	Implementation of Phase-II for Centre for Chemical Biology and Therapeutics (CCBT) (8274-Prof. Ashok Venkatarani)	8274	DBT	9,57,478	1,10,42,005	-	-	-	1,44,00,822	-	-	1,44,00,822	-24,01,339
53	Financial approval of the Swarna Jayanti Fellowship to Dr. Dasarathi Palakodeti (8275-Dasarathi Palakodeti)	8276	DST	-36,878	-	-	-	-	-	-	-	-	-36,878
54	Role of Mechanical Signaling in Maintaining Stem Cell Quiescence in Mouse Skin (8277-Sridha Rathavan)	8277	SERB	-8,07,594	-	-	-	-	-	-	-	-	-8,07,594
55	Indo French Centre for Promotion of Advances Research-ICFPCAR (8279-Dr. Mihail S)	8279	CEFPARA	-2,99,319	2,99,319	-	-	-	-	-	-	-	-0
56	Structure-Function Studies on Nucleotide Sugar Transporters (8291-5 Ramaswamy)	8291	SERB	-6,69,094	-	-	-	-	-	-	-	-	-6,69,094
57	N PDF Fellowship to Dr. Venkatarani R. Gov (8454)	8454	SERB	-5,20,166	-	-	-	-	-	-	-	-	-5,20,166
58	Elucidating the function of the eukaryotic histone lysine methyltransferase 1 (EHMT 1) in obesity and diabetes (8455 Mahua Chakraborty)	8455	DST	-8,99,103	-	-	-	-	-	-	-	-	-8,99,103
59	8456 Tina Mukherjee	8456	CEFPARA	-5,49,746	-	-	-	-	-	-	-	-	-5,49,746
60	Regulation of damage-induced cellular plasticity in the lung (8459 Arjun Gulai)	8458	SERB	5,098	-	-	-	-	-	-	-	-	5,098
61	Characterization of novel variant human embryonic stem cells with features of neoplastic progression (8460 Shrivani Ranganelli)	8460	SERB	12,387	-	-	-	-	-	-	-	-	12,387
62	Dissecting the Role of Chromatin Remodeling Factor TIF5G in regulation of regeneration in Planaria (8461 Bharti Jaywal)	8461	DBT	-1,08,798	-	-	-	-	-	-	-	-	-1,08,798
63	Molecular, structural and functional mapping of eye regeneration using novel light sensing assays (8463 Akash Guliyani)	8463	SERB	-2,27,284	-	-	-	-	-	-	-	-	-2,27,284
64	Fabrication of Catalytic nano-fibre based facemask and clothing to prevent pesticide-induced neuronal dysfunction and mortality (8468-Prof. Praveen Kumar Venkata)	8468	DBT	26,879	7,33,678	-	-	23,870	-	-	-	7,33,678	3,009
65	Proliferation of Bromodomain specific interacting partners using unnatural amino acid mutagenesis (Ramalingeswamy Fellowship) (8473-Dr. Sonia Sen)	8473	DBT	5,45,885	8,00,000	-	-	-	-	-	-	9,57,113	3,88,742
66	Inducible gene drive based approach to control infectious insect vector (8480-Dr. Bakkar Bakthavatsali)	8480	BIRAC	-3,45,323	6,00,000	2,54,677	-	-	-	-	-	-	-
67	Leveraging stem cell technology to facilitate discovery for human disease biology in India (8479-Prof. Anurva Saini/Prof. Raghun Padinath)	8479	DBT	4,27,815	51,21,992	46,64,720	-	4,04,427	-	-	-	26,71,975	-21,91,315
68	Regulation of metabolic homeostasis by Trna modifications (8483-Dr. Sunil Saxena)	8483	SERB	5,38,810	-	-	-	-	-	-	-	-	-17,295
69	Delineating the Immune-Epithelial Crosstalk in Embryonic Stem (8484-Dr. Srichala Rathavan/Dr. Dasarathi Palakodeti)	8484	DBT	55,253	11,96,804	13,13,196	-	-	-	-	-	10,40,566	-11,01,705
70	Architecture of axonemal doublet microtubule inner junction (8485-Dr. Mihail Sridinidin)	8485	SERB	3,93,602	-	-	-	-	-	-	-	6,48,520	-2,54,918
71	Understanding selective drug mechanisms using hypertrophic patient-specific induced pluripotent stem cell (iPsc)-derived cardiomyocytes (8487-Dr. Dhandaanu)	8487	SERB	1,08,240	-	-	-	-	-	-	-	1,08,240	0
72	High-affinity binders against Covid 19 spike protein using display libraries (8492)	8492	DBT	-7,97,292	9,920	-	-	-	-	-	-	-	-7,87,372
73	COVID-19 Biomarkers (8493)	8493	DBT	7,66,098	4,20,011	10,68,641	-	36,562	-	-	-	2,19,200	-1,38,294
74	Chromatin regulation of human cortical development by LSD1 and its role in intellectual disability (8494)	8494	SERB	64,209	0	60,473	-	-	-	-	-	3,736	-0
75	Single cell metabolic maps of senescent cells and senescence driven gene sets in aging (8495)	8495	SERB	-6,89,701	-	-	-	-	-	-	-	2,64,997	-9,54,698
76	Epigenetic Regulation of the Wound Healing Program (8498)	8498	DBT	15,995	53,24,510	40,46,773	-	15,995	-	-	-	39,07,062	-40,79,637
77	National Post Doctoral fellowship awarded to Dr. Shalini Sarval (8500)	8500	SERB	24,577	-	24,577	-	-	-	-	-	-	0
78	Characterize the role of Angiogenin and Trna derived small RNAs in early embryogenesis (8502)	8502	DBT	1,14,444	24,06,585	11,27,211	-	70,783	-	-	-	26,83,201	-13,60,166



Sl No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2024
79	Genomic Surveillance for SARS-Cov-2 in India: Indian SARS-Cov-2 Genomics Consortium (INSACOG) (8503)	8503	DBT	3,03,186	46,40,661	-	45,84,858	3,03,186	-	-	-	55,803	-
80	Deciphering the molecular mechanisms of dysregulation caused by mutations in LSD1 leading to Intellectual Disability (IYBA-2022)	8605	DBT	38,367	10,86,067	-	8,73,084	-	-	-	-	10,72,966	-8,21,616
81	Pre-Clinical evaluation of promising drugs for a rare syndromic cardiomyopathy in children.	8606	BIRAC	-3,16,122	9,99,600	-	-	-	-	-	-	18,74,378	-11,90,900
82	Translational platforms for discovery, repurposing and clinical development for Covid-19 therapeutics.	8607 & 8608	DBT	5,62,746	1,58,00,220	-	92,73,625	5,62,746	87,16,153	-	-	1,06,72,669	-41,46,074
83	Immune Cell lipid homeostasis by the Notch pathway functions as a central regulator of animal growth control both in homeostasis and conditions of dietary stress.	8609	SERB	3,50,505	-	-	1,342	-	-	-	-	4,24,757	-72,910
84	Novel micropatterned cardiac organoid model for deciphering the pathophysiology of cardiomyopathy	8610	SERB	-43,000	10,68,400	-	-	-	-	-	-	8,40,153	1,85,247
85	Faculty Travel/Award to Dr. Tina Mukherjee	8611	DBT	87,454	26,81,659	-	2,07,498	52,827	9,97,100	-	-	27,54,667	-2,45,889
86	Faculty Travel/Award to Dr. Tina Mukherjee for collaboration visit of Prof. Ramas	8613	SERB	101	-	-	-	-	-	-	-	-	101
87	Elucidating the Structural and Functional Characterization of Membrane and Envelope Protein from SARS COV-2 and its variants in Virus like Particle formation and its role in the virus assembly and release.	8615	SERB	59,243	-	-	59,243	-	-	-	-	-	-
88	The role of Galectin-3/GAL3 in mediating epithelial defences against urinary tract infection by constitutive activation of the NF-κB pathway	8616	ICMR	2,47,132	12,80,974	-	18,900	-	-	-	-	12,73,048	2,73,958
89	Enabling Covid-19 vaccine and therapeutics development using animal models	8617	SERB	5,00,471	10,00,000	-	4,919	-	-	-	-	9,60,337	5,45,063
90	Developing CRISPR-Cas9 based genome engineering technology for homology independent genetic manipulation at endogenous genomic loci in a tissue specific manner.	8618	BIRAC	3,40,59,313	-	-	3,20,807	-	1,11,53,263	-	-	1,11,53,263	2,32,26,857
91	Development of machine for rapid fabrication of the biocompatible micro needles, followed by clinical testing u	8619	DBT	-	15,12,205	-	11,65,020	-	-	-	-	4,65,721	-1,18,536
92	NPDF Fellowship of Shahbir Ahmad	8628	SERB	10,22,720	-	-	-	-	-	-	-	9,58,192	64,528
93	Functional genomics of congenital heart disease	8629	SERB	8,22,330	36,01,440	-	4,537	-	1,85,900	-	-	9,20,802	-93,935
94	Genomic Surveillance for SARS-Cov-2 in India: Indian SARS-Cov-2 Genomics Consortium (INSACOG) - Phase II	8631	DBT	-	10,67,798	-	-	-	32,11,730	-	-	32,11,730	-6,78,088
95	Forcesun nanofiber yarns incorporated with stem cell strips as cardiac path for Myocardial Infarction - Dr. Arshi N	8635	DBT	63,903	48,87,600	-	-	-	29,55,130	-	-	29,55,130	19,91,373
96	Elucidating the functional role of RBP4 in regulating neocortical development and its neuropathological role in autism spectrum disorder - Dr. Sreeta Kumari Dhanva	8640	DBT	-	29,00,000	-	17,26,832	-	-	-	-	15,87,572	-4,14,404
97	Insights into the pathogenesis and long-term effects of SARS-Cov-2 variants from structural and immunological perspectives enabling the development of new antiviral modalities	8641	DBT	-	29,00,000	-	16,35,775	-	10,00,000	-	-	25,85,866	-13,21,641
98	Elucidating the role of Ruidira/BCAS3 in endothelial cell-cardiovascular cross-talk and coronary artery disease	8644	BIRAC	-	63,87,000	-	1,04,248	-	-	-	-	13,78,244	51,13,004
99	Development of Novel Cre Reporter Mice Models for Non-Invasive Whole Body Live Imaging for Preclinical Studies	8645	SERB	-	10,93,412	-	7,669	-	-	-	-	10,37,858	63,223
100	Teachers Associationship for Excellence to Dr. Ashish Gupta	8646	SERB	-	17,56,000	-	28,407	-	0	-	-	1,63,680	16,20,727
101	Repurposing anti-diabetic drug and related rescue mechanisms for glycogen storage cardiomyopathy	8637	SERB	-	3,35,000	-	5,230	-	0	-	-	3,12,211	28,019
102	Role of posttranslational modifications of non-tubulin substrates in regulating mammalian cilium function	8647	ICMR	-	22,69,544	-	28,711	-	-	-	-	1,95,888	21,02,367
103	Metabolic exchange and resource sharing strategies in self-organized cellular communities	8648	SERB	-	12,81,268	-	16,689	-	-	-	-	-	12,97,957
104	Creation of a national network of existing and upcoming high risk pathogens laboratories (BSL-3/4) labs across departments and keeping their "interlinkages" functional for use during outbreak response across sectors" under NDRM component of PM-ABHM	8649	DBT	-	7,00,000	-	-	-	-	-	-	-	-
105	Faculty Travel/Award to Dr. Tina Mukherjee	8650	ICMR	-	50,79,600	-	22,054	-	-	-	-	-	51,01,654
<b>Total : (A)</b>				4,28,95,836	12,39,79,153	-	5,87,37,513	18,01,661	2,34,52,728	-	-	8,52,26,242	2,16,73,086
<b>B</b>				-	-	-	-	-	-	-	-	-	-
106	From other than Government	-	-	-	-	-	-	-	-	-	-	-	-
107	Workshop on X-Ray Crystallography (8232-Dr. Vinod Nayak)	8223	AVANTOR	1,14,591	-	-	-	-	-	-	-	1,14,591	-
108	Regulation of epithelial stem cell homing in cutaneous wound healing (8226- Dr. Subhasri Ghosh)	8226	WT/DBT IA	-1,59,784	-	-	-	-	-	-	-	-	-1,59,784
109	Research Project awarded by Core1 (8232- Dr. Colin Jamora)	8232	L'OREAL	14,76,452	-	-	64,711	-	-	-	-	10,30,245	5,10,918



Sl.No.	Project Title (Name of PI if applicable)	Budget code	Funding Agency	Opening Balance	Received during the year	Refund during the year	Interest received	Interest Refunded	Expenditure	Advance	Adjustment	Total Expenditure	Balance as on 31-03-2024
110	Agreement with Unilever (8245-Dr. Colin Jamral)	8245	Unilever Industries	18,17,388	2,75,000	-	41,345	-	16,71,439	-	-	16,71,439	4,62,294
111	Innovative multi-modal approach to identify novel candidate genes and small chemical molecules for cardiomyopathies (8278-Dr. P. Dhandapani)	8278	WT/081 IA	12,42,040	14,96,924	-	-	-	27,38,664	-	-	27,38,664	0
112	Scientists without boundaries at the Bangalore life science cluster (8283)	8283	TTK	46,50,400	-	-	-	-	46,50,123	-	-	46,50,123	277
113	Metabolic Regulation of Fungal Morphogenesis (8286-Dr. Sriram V)	8286	WT/081 IA	31,217	-	-	-	-	-	-	-	-	31,217
114	Structural & Development Trust (8292)	8292	TIGS	-53,94,755	3,55,52,323	-	-	-	43,60,142	-	-	1,63,30,149	1,38,30,419
115	Structural and functional insights into bacterial silicic acid transport (8293-Dr. Praveen Govil)	8293	WT/081 IA	5,69,293	2,22,593	-	-	-	7,91,886	-	-	7,91,886	0
116	Support world class research in Neurobiology (8467-Prof. Apurva Sami)	8467	Prathika Trust	2,01,02,771	-	-	9,71,859	-	67,72,273	-	-	67,72,273	1,43,02,357
117	Donation from Kiran Mazumdar, Shah(8474-Prof. Apurva Sami)	8474	Kiran Mazumdar Shah	2,15,62,144	-	-	12,36,240	-	6,66,840	-	-	6,66,840	2,21,31,544
118	Regulation of cerebral cortical development by chromatin modifiers in health and disease (8475-Dr. Bhavana Muralidhara)	8475	WT/081 IA	15,26,641	37,17,102	-	45,317	63,937	2,57,482	-	-	50,79,058	1,46,065
119	Joint Agreement between Instem and Evestem (8482-Dr. Arjun Gulal)	8482	Evestem-Camp	2,26,809	-	-	-	-	-	-	-	-	2,26,809
120	Gates Foundation Grant-8242	8242	GF	4,66,895	-	-	-	-	4,66,895	-	-	4,66,895	-
121	Fraxa-8247	8247	FRAXA	1,72,978	-	-	-	-	1,72,978	-	-	1,72,978	-
122	Results of EMBO Young Investigator Programme selections- 2015 (8275-Minhabuddin Strajuddin)	8275	EMBO	22,41,922	-	-	1,01,181	-	4,30,743	-	-	4,30,743	19,11,360
123	Simons Autism Research Project (8282-Sumatra Chatterji)	8282	EDINBURGH	78,484	-	-	-	-	-	-	-	-	78,484
124	Develop an insect (Moaquito) repellent formulation based on the natural insecticide moaktalone-8288 Praveen Vemula	8288	MANUS	3,94,349	-	-	19,905	-	16,437	-	-	16,437	3,97,817
125	Director's Discretionary Fund (8296)	8296	FLEXI	94,45,351	4,66,895	-	3,81,541	-	38,19,309	-	-	38,19,309	64,17,405
126	Burgwort Ltd 8457 Ramaswamy	8457	BUGWORTK	1,00,202	-	-	-	-	19,833	-	-	19,833	80,474
127	Terumo Inc. (8468) Mahendra Rao	8468	Terumo	23,71,119	-	-	-	-	23,71,119	-	-	23,71,119	0
128	Collaborative Agreement between Artus & Instem (8472-Dr. Praveen Kumar Vemula)	8472	Artus/ Funded	2,45,467	99,16,927	-	1,67,595	-	46,26,972	-	-	46,26,972	57,02,927
129	CSIR & Project Cori Contingency	-	-	5,72,013	-	-	-	-	-	-	-	-	5,72,013
130	Early Career Fellowship to Dr. Anuree Mahanta (8486)	8486	WT/081 IA	5,98,546	28,86,390	-	7,784	39,349	23,76,525	-	-	23,76,525	10,76,746
131	TIGS Covid Testing Fund (8488)	8488	TIGS	11,46,701	-	-	-	-	11,46,701	-	-	11,46,701	0
132	Investigation of Diagnostics (INDX) (8497)	8497	C-CAMP	0	-	-	-	-	-	-	-	-	0
133	Investigation of the Susceptibility UPRKA-Mouse Airways Cells to AIG1+ALG12 (8499)	8499	Genetech	26,354	-	-	-	-	-	-	-	-	26,354
134	EMBO Global Investigator Network (8501)	8501	EMBO	9,16,296	2,70,462	-	41,943	-	4,68,730	-	-	4,68,730	7,59,971
135	Covid RT-PCR for Saliva Samples	8602	CMC Vellore/ NCB/CCAMP	1,18,14,997	-	-	4,55,090	-	60,64,662	-	-	60,64,662	62,06,435
136	Establish assay and research capabilities (As per agreement)	8604	Mitoscience Research Pvt Ltd	5,36,331	8,333	-	28,272	-	4,37,880	-	-	4,37,880	5,72,936
137	Anti SARS Activity Service Pipeline	8612	C-CAMP	4,20,155	-	-	4,001	-	26,95,184	-	-	26,95,184	-12,724
138	EMBO Meeting for Organoid meeting 06.02.23-09.02.2023	8614	EMBO	22,79,387	5,71,911	-	-	-	1,56,114	-	-	28,51,298	0
139	NUS	8621	NUS	40,99,278	9,76,507	-	13,338	-	64,50,608	-	-	64,50,608	-14,10,885
140	USIAS	8622	USIAS	11,01,229	-	-	-	-	11,01,229	-	-	11,01,229	0
141	Understanding and manipulating how resource allocations drive collective cell functions.	8623	Welcome Trust	1,35,40,249	21,90,135	-	4,42,257	-	45,41,952	-	-	45,41,952	1,16,30,689
142	Role of tubulin posttranslational modifications in regulating primary cilia functions in wound healing and tissue homeostasis	8625	Welcome Trust	43,44,042	91,89,976	-	2,63,847	-	67,81,623	-	-	1,11,35,304	28,62,513
143	Regulation of immune defenses and homeostasis at the urethral barrier	8626	Welcome Trust	7,10,051	34,87,351	-	65,464	-	37,09,530	-	-	38,08,330	4,54,536
144	Immune cells as mobile sensors of animal physiology	8627	Welcome Trust	-	74,00,505	-	1,20,560	-	17,62,698	-	-	17,62,698	57,58,367
145	Project Title to be Filled	8630	Evestem Camp	-	20,000	-	-	-	1,09,688	-	-	1,09,688	-89,688
146	Project Title to be Filled	8630	GATC	-	7,51,563	-	-	-	7,75,272	-	-	7,75,272	-23,709
147	Project Title to be Filled	8630	GSBTM	-	7,00,000	-	-	-	7,06,004	-	-	7,06,004	-6,004
148	IRMI Research Management Grant	8632	Welcome Trust	-	9,80,000	-	25,311	-	8,07,987	-	-	8,07,987	1,97,924
149	IRMI TRAVEL GRANT	8632	Welcome Trust	-	2,73,185	-	-	-	2,73,185	-	-	2,73,185	-
150	Establishing the causal relationship between genetic disease risk variants of Gene SPTN4 and its underlying molecular neuropathological role in bipolar disorder	8633	Welcome Trust	-	33,99,972	-	84,789	-	18,59,606	-	-	18,59,606	16,25,155
151	SUBAWARD AGREEMENT NO. 5123689 BETWEEN THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL AND Institute for Stem Cell Science and Regenerative Medicine	8634	SVCF- C2I	-	51,04,222	-	-	-	61,15,851	-	-	61,15,851	-10,11,629
152	A Gram-positive Macrophage Enzyme Responsive Immunosuppressive Therapy (MERIT) to prevent chronic rejection in vascularized composite Allotransplantation	8635	DBT - DOD	-	1,14,13,288	-	99,16,927	-	14,96,361	-	-	14,96,361	-
153	"Organization principles governing the assembly and function of contractile units across scales"	8638	India Alliance	-	1,03,99,427	-	1,49,654	-	30,53,772	-	-	30,53,772	74,95,309
154	Exploiting the evolution and physiology of the olfactory-immune system connection	8639	HFSP	-	1,02,84,720	-	2,70,701	-	38,08,149	-	-	55,11,034	50,44,387
155	Enabling generalizable, stem cell-based Target Assessment Packages (AMPs)	8642	BMGF	-	12,07,22,520	-	27,38,420	-	96,26,182	-	-	96,26,182	11,38,34,758
156	Agreement between Instem and Incha	8652	IMCB	-	24,53,830	-	42,616	-	-	-	-	-	24,96,446
157	Project Title to be Filled - Praveen K Vemula	8652	MAHE	-	9,58,608	-	-	-	-	-	-	-	9,58,608
	Sub Total: (C)			10,53,37,718	24,60,93,221	-	77,84,851	1,03,286	1,09,29,104	-	-	12,18,79,294	22,72,59,200
	Grand Total: (A+B+C-D)			14,82,33,553	37,00,72,274	-	6,87,11,523	83,48,364	19,04,947	3,43,81,832	17,27,23,704	20,71,05,536	24,89,32,285




**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
 (Registered under the Karnataka Societies' Registration Act.)  
 GKVK, BELLARY ROAD, BANGALORE - 560 065  
**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE -4 - SECURED LOANS AND BORROWINGS:</b>		
1. Central Government	-	-
2. State Government (Specify)	-	-
3. Financial Institutions	-	-
(a) Term Loans	-	-
(b) Interest accrued and due	-	-
4. Banks	-	-
(a) Term Loans	-	-
- Interest accrued and due	-	-
(b) Other Loans (Specify)	-	-
- Interest accrued and due	-	-
5. Other Institutions and Agencies	-	-
6. Debentures and Bonds	-	-
7. Others (Specify)	-	-
<b>TOTAL</b>	-	-

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE -5 - UNSECURED LOANS AND BORROWINGS:</b>		
1. Central Government	-	-
2. State Government (Specify)	-	-
3. Financial Institutions	-	-
(a) Term Loans	-	-
(b) Interest accrued and due	-	-
4. Banks	-	-
(a) Term Loans	-	-
- Interest accrued and due	-	-
(b) Other Loans (Specify)	-	-
- Interest accrued and due	-	-
5. Other Institutions and Agencies	-	-
6. Debentures and Bonds	-	-
<b>TOTAL</b>	-	-
Note: Amounts due within one year		

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE-6 - DEFERRED CREDIT LIABILITIES</b>		
a) Acceptances secured by hypothecation of capital equipment and other assets.	-	-
b) Others	-	-
<b>TOTAL</b>	-	-
Note: Amounts due within one year		



INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE  
(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024

		(Amount- Rs.)	
SCHEDULE -7 CURRENT LIABILITIES AND PROVISIONS		CY 2023-24	PY 2022-23
<b>A. CURRENT LIABILITIES</b>			
1. Acceptances		-	-
2. Sundry Creditors		-	-
(a) For Goods		1,12,48,614	2,90,07,633
(b) Others		2,06,06,664	41,49,321
3. Advance Received		-	-
4. Interest accrued but not due on:		-	-
(a) Secured Loans/Borrowings		-	-
(b) Unsecured Loans /borrowings		-	-
5. Statutory Liabilities :		-	-
(a) Overdue		-	-
(b) Others		28,87,316	18,97,236
6. Other Current Liabilities		1,23,63,788	3,26,19,236
	<b>TOTAL (A)</b>	<b>4,71,06,382</b>	<b>6,76,73,426</b>
<b>B. PROVISIONS</b>			
1. For Taxation		-	-
2. Gratuity		27,68,750	-
3. Superannuation/Pension		-	-
4. Accumulated Leave Encashment		19,19,338	-
5. Trade Warranties/Claims		-	-
6. Others		13,45,425	66,41,399
	<b>TOTAL (B)</b>	<b>60,33,513</b>	<b>66,41,399</b>
	<b>Grand TOTAL (A+B)</b>	<b>5,31,39,895</b>	<b>7,43,14,825</b>



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE, BANGALORE**  
(Registered under the Karnataka Societies' Registration Act)

GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULE FORMING PART OF BALANCE SHEET FOR THE PERIOD ENDED MARCH 31, 2024**

**SCHEDULE - 8**

DESCRIPTION	GROSS BLOCK				DEPRECIATION				NET BLOCK		
	As on 1-4-2023	Additions	Deductions	Up to 31-03-2024	Rate	As on 1-4-2023	Additions	Deductions	Upto 31-03-2024	As on 31-03-2024	As on 31-03-2023
<b>(A) Own Funds</b>											
Land Development Works	17,01,110	-	-	17,01,110	0%	7,97,071	-	-	7,97,071	9,04,039	9,04,039
Land (Nominal Value)	1	-	-	1	0%	-	-	-	-	1	1
Other Misc. facilities	25,26,642	-	-	25,26,642	10%	15,47,770	97,887	-	16,45,657	8,80,985	9,78,872
Buildings (Residential)*	19,30,49,174	-	-	19,30,49,174	5%	7,08,83,986	61,08,259	-	7,69,92,245	11,60,56,929	12,21,65,188
Buildings(Non-Residential)	11,96,25,797	66,31,754	-	12,62,57,551	10%	7,27,10,537	53,54,701	-	7,80,65,238	4,81,92,313	4,69,15,260
Buildings(Non-Residential)- WIP	-	62,88,767	-	62,88,767	0%	-	-	-	-	62,88,767	-
Laboratory Equipment	72,07,21,355	3,68,18,415	-	75,75,39,770	15%	39,35,15,912	4,99,21,909	-	44,34,37,820	31,41,01,950	32,72,05,443
Laboratory Equipment(Work in Progress)	-	1,23,22,223	-	1,23,22,223	0%	-	-	-	-	1,23,22,223	-
Computer Equipment	1,68,47,676	56,31,761	-	2,24,79,437	40%	82,27,701	48,31,508	-	1,30,59,209	94,20,228	86,19,975
Offices Equipment	84,54,297	91,79,768	-	1,76,34,065	15%	48,16,189	10,28,012	-	58,44,201	1,17,89,864	36,38,108
Furniture & Fixture	2,26,16,498	3,31,801	-	2,29,48,299	10%	83,60,372	14,52,268	-	98,12,641	1,31,35,658	1,42,56,126
Capital / Building	2,04,75,25,028	-	-	2,04,75,25,028	10%	82,92,75,750	12,18,24,927	-	95,11,00,683	1,09,64,24,345	1,21,82,49,272
<b>Sub Total (A)</b>	<b>3,13,30,67,578</b>	<b>7,72,04,489</b>	<b>-</b>	<b>3,21,02,72,067</b>		<b>1,39,01,35,293</b>	<b>19,06,19,472</b>	<b>-</b>	<b>1,58,07,54,765</b>	<b>1,62,95,17,302</b>	<b>1,74,29,32,284</b>
<b>(B) Project Funds</b>											
Furniture & Fixture	3,15,984	-	-	3,15,984	10%	2,28,253	8,773	-	2,37,026	78,958	87,731
Office Equipment - WIP	-	71,28,496	-	71,28,496	0%	-	-	-	-	71,28,496	-
Laboratory Equipment	1,06,28,37,684	1,01,52,274	-	1,07,29,89,958	15%	66,11,04,238	6,09,78,412	-	72,20,82,650	35,09,07,308	40,17,33,446
Laboratory Equipment - WIP	-	1,16,12,263	-	1,16,12,263	0%	-	-	-	-	1,16,12,263	-
Buildings(Non-Residential)- WIP	-	54,88,799	-	54,88,799	0%	-	-	-	-	54,88,799	-
Buildings(Non-Residential)	18,97,91,403	-	-	18,97,91,403	10%	6,51,45,814	1,24,64,559	-	7,76,10,373	11,21,81,030	12,46,45,589
<b>Sub Total (B)</b>	<b>1,25,29,45,071</b>	<b>3,43,81,832</b>	<b>-</b>	<b>1,28,73,26,903</b>		<b>72,64,78,305</b>	<b>7,34,51,744</b>	<b>-</b>	<b>79,99,30,049</b>	<b>48,73,96,854</b>	<b>52,64,66,766</b>
<b>(C) CSCR -Vellore</b>											
Buildings	2,46,00,000	-	-	2,46,00,000	10%	61,10,267	18,48,973	-	79,59,240	1,66,40,760	1,84,89,732
Laboratory Equipment	33,16,78,879	3,40,89,301	-	36,57,68,180	15%	20,66,63,194	2,10,70,130	-	22,77,33,324	13,80,34,856	12,50,15,909
Computer Equipment	3,57,46,731	13,85,910	-	3,71,32,641	40%	3,57,46,476	3,22,885	-	3,60,69,361	10,63,280	255
Furniture & Fixture	7,875	-	-	7,875	10%	5,267	261	-	5,528	2,347	2,608
<b>Sub Total (C)</b>	<b>39,20,33,485</b>	<b>3,54,75,211</b>	<b>-</b>	<b>42,75,08,696</b>		<b>24,85,25,204</b>	<b>2,32,42,249</b>	<b>-</b>	<b>27,17,67,453</b>	<b>15,57,41,243</b>	<b>14,35,08,504</b>
<b>(D) Wadhvani Foundation</b>											
Laboratory Equipment	6,84,372	-	-	6,84,372	15%	4,84,165	30,031	-	5,14,196	1,70,176	2,00,207
Computer Equipment	8,48,633	-	-	8,48,633	40%	8,48,164	188	-	8,48,352	281	469
<b>Sub Total (D)</b>	<b>15,33,005</b>	<b>-</b>	<b>-</b>	<b>15,33,005</b>		<b>13,32,329</b>	<b>30,219</b>	<b>-</b>	<b>13,62,548</b>	<b>1,70,457</b>	<b>2,00,676</b>
<b>Grand Total (A+B+C+D)</b>	<b>4,77,95,79,139</b>	<b>14,70,61,532</b>	<b>-</b>	<b>4,92,66,40,671</b>		<b>2,36,64,71,131</b>	<b>28,73,43,683</b>	<b>-</b>	<b>2,65,38,14,815</b>	<b>2,27,28,25,856</b>	<b>2,41,31,08,230</b>

Note 1 : This represents Total additions made to the Fixed Assets during the year, consisting of Rs. 11,26,79,700/- (FY 22-23 Rs. 17,71,42,282/-) acquired out of Core Funds and Rs.3,43,81,832/- (FY 22-23 Rs.74,35,905/-) acquired out of Project Funds.  
 Note 2 : This represents the Depreciation on Fixed Assets for the year, consisting of Rs.21,38,61,721/- (FY 22-23 Rs.22,39,83,122/-) on Fixed Assets acquired out of Core Funds & Rs.7,34,81,963/- (FY 22-23 Rs.8,53,17,361/-) on Fixed Assets acquired out of Project Funds.  
 \*The residential building (50 Nos. Flats) at CBISite Yelahanka is constructed jointly by NCBS and inStem and the land on which it is constructed belong to NCBS. The cost is shared between both the Institutes and there is an MoU signed between both the Institutes to this effect.  
 Depreciation on 01.04.2023 of CSCR is adjusted include Rs.223 which was short considered during 2022-23.





**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
 (Registered under the Karnataka Societies' Registration Act.)  
 GKVK, BELLARY ROAD, BANGALORE - 560 065  
**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**


		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE -9 - INVESTMENTS FROM EARMARKED /ENDOWMENT FUNDS</b>			
1.	In Government Securities	-	-
2.	Other approved securities	-	-
3.	Shares	-	-
4.	Debentures and Bonds	-	-
5.	Subsidiaries and Joint Ventures	-	-
6.	Others (to be specified)	-	-
<b>TOTAL</b>		-	-

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE -10 - INVESTMENT OTHERS</b>			
1.	In Government Securities	-	-
2.	Other approved securities	-	-
3.	Shares	-	-
4.	Debentures and Bonds	-	-
5.	Subsidiaries and Joint Ventures - Shares of C-CAMP- (Company registered under Section 8 Company Act )	600	600
6.	Others (to be specified)	-	-
<b>TOTAL</b>		600	600



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
 (Registered under the Karnataka Societies' Registration Act.)  
 GKVK, BELLARY ROAD, BANGALORE - 560 065  
**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

	CY 2023-24	PY 2022-23
<b>SCHEDULE -11 - CURRENT ASSETS, LOANS, ADVANCES ETC.</b>		
<b>A. CURRENT ASSETS:</b>		
1. Inventories:		
a) Stores and Spares	-	-
b) Loose Tools	-	-
c) Stock-in-trade	-	-
Finished Goods	-	-
Work -in-progress	-	-
Raw Materials	-	-
2. Sundry Debtors:		
a) Debts outstanding for above six months	19,60,712	2,07,835
b) Others	46,17,840	2,56,806
3. Cash balances in hand (including cheques/drafts)	0	24
4. Bank Balances:		
a) With Scheduled Banks:		
- On current Accounts	3,61,49,246	90,21,512
- On Deposits Accounts(includes margin money	20,28,71,004	3,05,97,889
- On Savings Accounts	7,14,80,461	12,04,67,505
b) With Non-Scheduled Banks:		
- On current Accounts	-	-
- On Deposits Accounts(includes margin money	-	-
- On Savings Accounts	-	-
5. Post Office Savings Accounts	-	-
<b>TOTAL (A)</b>	<b>31,70,79,263</b>	<b>16,05,51,571</b>
<b>B. LOANS, ADVANCES AND OTHER ASSETS</b>		
1. Loans:		
a) Staff	-	-
b) Other Entities engaged in activities /	-	-
Objectives similar to that of the Entity	-	-
c) Others (specify)	-	-
2. Advances and other amounts recoverable in cash or in kind or for value to be received:		
a) On Capital Account	1,31,63,358.00	-
b) Prepayments	-	-
c) Others	3,39,04,107	2,93,13,939
3. Income Accrued:		
a) On investments from earmarked/endow. Funds	-	-
b) On investments - others	38,51,972	1,07,530
c) On Loans & Advances	-	-
d) Others	-	-
4. Claims Receivable:	1,53,01,986	62,09,610
<b>TOTAL (B)</b>	<b>6,62,21,423</b>	<b>3,56,31,079</b>
<b>GRAND TOTAL (A+B)</b>	<b>38,33,00,685</b>	<b>19,61,82,650</b>



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
(Registered under the Karnataka Societies' Registration Act.)  
GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE -12 : INCOME FROM SALES AND SERVICES</b>		
1) Income from Sales	-	-
a) Sale of Finished Goods	-	-
b) Sale of Raw Material	-	-
c) Sale of Scraps	-	-
2) Income from Services:		
a) Labour and Processing Charges	-	-
b) Professional /Consultancy Services	-	-
c) Agency Commission and Brokerage	-	-
d) Maintenance Services (Equipment/ Property)	-	-
e) Others (Facility User charges)	2,60,52,807	1,08,72,378
<b>TOTAL</b>	<b>2,60,52,807</b>	<b>1,08,72,378</b>

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE -13: GRANTS/SUBSIDIES (Irrevocable Grants and Subsidies received)</b>		
1) Central Government	51,23,00,000	34,41,32,896
2) State Government(s)	-	-
3) Government Agencies	-	-
4) Institutions/Welfare Bodies	-	-
5) International Organizations	-	-
6) Others (specify)-PNB	-	-
<b>TOTAL</b>	<b>51,23,00,000</b>	<b>34,41,32,896</b>

	(Amount- Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE-14: FEES/SUBSCRIPTIONS</b>		
1. Entrance Fees	-	-
2. Annual Fees/Subscriptions	-	-
3. Seminar/Programme Fees	-	-
4. Consultancy Fees	-	-
5. Others (Specify)	-	-
<b>TOTAL</b>	<b>-</b>	<b>-</b>



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE-15: INCOME FROM INVESTMENTS</b>			
<b>A. Investment from Earmarked Fund</b>			
1) Interest		-	-
	a) On Govt. Securities	-	-
	b) Other Bonds/Debentures	-	-
2) Dividends		-	-
	a) On Shares	-	-
	b) On Mutual Fund Securities	-	-
3) Rents		-	-
4) Others (Specify)		-	-
	<b>TOTAL (A)</b>	-	-
<b>B. Investment-Others</b>			
1) Interest		-	-
	a) On Govt. Securities	-	-
	b) Other Bonds/Debentures	-	-
2) Dividends		-	-
	a) On Shares	-	-
	b) On Mutual Fund Securities	-	-
3) Rents		-	-
4) Others (Specify)		-	-
	<b>TOTAL (B)</b>	-	-
	<b>Total of income from investment (A+B)</b>	-	-

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE - 16: INCOME FROM ROYALTY, PUBLICATIONS ETC.</b>			
1) Income from Royalty		-	-
2) Income from Publications		-	-
3) Others (Specify)		-	-
	<b>TOTAL</b>	-	-



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**

(Registered under the Karnataka Societies' Registration Act.)

GKYK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE - 17 : INTEREST EARNED</b>			
<b>1) On Term Deposits:</b>			
a) With Scheduled Banks	15,07,925	66,732	
b) With Non-Scheduled Banks	-	-	
c) Interest of CSCR Vellore	-	-	
d) Others	-	-	
<b>2) On Savings Accounts:</b>			
a) With Scheduled Banks	6,31,000	15,39,668	
b) With Non-Scheduled Banks	-	-	
c) With Institutions	-	-	
d) Others	-	-	
<b>3) On Loans:</b>			
a) Employees /Staff	-	-	
b) Others	-	-	
<b>4) Interest on Debtors and Other Deposits</b>	<b>2,46,717</b>	<b>2,39,375</b>	
<b>TOTAL</b>	<b>23,85,642</b>	<b>18,45,775</b>	

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE - 18: OTHER INCOME</b>			
<b>1) Profit on Sale /disposal of Assets:</b>			
a) Owned assets	-	-	
b) Assets acquired out of grants, or received free of cost	-	-	
<b>2) Export Incentives realized</b>			
3) Recovery - EMG Overheads	53,00,937	40,39,619	
4) Fees for Miscellaneous Services	5,85,934	60,698	
5) Miscellaneous Income *	21,46,766	55,34,232	
6) Net Gain/Loss from foreign currency Transaction	8,488	-	
<b>TOTAL</b>	<b>80,42,125</b>	<b>96,34,549</b>	

		(Amount- Rs.)	
		CY 2023-24	PY 2022-23
<b>SCHEDULE - 19: INCREASE/DECREASE IN STOCK OF FINISHED GOODS &amp; W.I.P</b>			
<b>a) Closing stock</b>			
- Finished Goods	-	-	
- Work-in-progress	-	-	
<b>TOTAL (A)</b>	<b>-</b>	<b>-</b>	
<b>b) Less: Opening Stock - Finished Goods</b>			
- Work-in-progress	-	-	
<b>Total (B)</b>	<b>-</b>	<b>-</b>	
<b>NET INCREASE/(DECREASE) (A+B)</b>	<b>-</b>	<b>-</b>	




**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE**  
(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULES FORMING PART OF BALANCE SHEET AS AT MARCH 31, 2024**

	(Amount - Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE - 20: ESTABLISHMENT EXPENSES</b>		
a) Salaries and Wages	13,14,62,027	10,75,02,291
b) Prior Period Salaries	-	-
c) Contribution to Provident Fund-NPS*	1,13,02,516	94,13,566
d) Contribution to other Fund (specify) - LS & Pension Contributions	51,27,519	89,27,600
e) Staff Welfare /expenses	1,99,783	14,31,817
f) Expenses on Employees' Retirement and Terminal Benefits	-	-
g) Others (specify)	-	-
h) Fellowships (JRF/SRF)	1,89,12,531	1,45,41,602
<b>TOTAL</b>	<b>16,70,04,376</b>	<b>14,18,16,876</b>

	(Amount - Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE - 21: OTHER ADMINISTRATIVE EXPENSES ETC.</b>		
a) Purchases - Laboratory & Computer Consumables	10,26,29,094	7,93,13,399
b) other Laboratory expenses	42,05,290	38,94,600
c) Membership Fees	14,01,400	11,85,938
d) Electricity and power	5,50,89,880	5,52,46,106
e) Water charges	30,21,090	30,41,007
f) Contract for Services-CSIR	82,94,972	68,38,739
g) Repairs & Maintenance	6,02,28,313	5,01,12,862
h) Training	-	-
i) Rent, Rates, Taxes and fees	19,03,183	95,47,219
j) Vehicles running and maintenance	6,48,000	6,48,000
k) Postage, Telephone and Communication charges	13,81,203	18,70,174
l) Printing and Stationery	13,84,751	12,00,707
m) Travelling & Conveyance Expenses	58,00,606	58,02,967
n) Expenses on Seminars/Workshops	23,59,278	8,82,082
o) Subscription Expenses	5,68,465	4,47,550
p) Expenses on Fees - Consultancy Fee/Honorarium	17,07,758	28,48,029
q) Auditors Remuneration	1,46,200	1,34,650
r) Hospitality Expenses	8,17,039	1,94,050
s) Security Charges	1,70,77,689	1,28,81,863
t) Bank Charges	41,979	46,099
u) Other Contingent Expenditure	34,69,316	23,70,158
v) Advertisement & Publicity	10,69,193	24,10,252
w) Sports facility management	-	-
x) Campus maintenance	1,52,33,267	1,32,69,889
y) Canteen Expenses	92,84,538	68,96,062
z) Professional fees	8,301	1,20,767
z) Other office Expenses	91,96,804	13,72,715
<b>TOTAL</b>	<b>30,69,67,609</b>	<b>26,25,75,884</b>




INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE BANGALORE  
(Registered under the Karnataka Societies' Registration Act.)

GKVK, BELLARY ROAD, BANGALORE - 560 065

SCHEDULES FORMING PART OF INCOME & EXPENDITURE ACCOUNT FOR THE YEAR ENDED MARCH 31, 2024

	(Amount - Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE - 22: EXPENDITURE ON GRANTS, SUBSIDIES ETC.</b>		
a) Grants given to Institutions/Organizations	-	-
b) Subsidies given to Institutions/Organizations	-	-
c) Expenditure incurred on Grants (As per Schedule -3)	17,27,23,704	16,34,06,279
<b>TOTAL</b>	<b>17,27,23,704</b>	<b>16,34,06,279</b>

	(Amount - Rs.)	
	CY 2023-24	PY 2022-23
<b>SCHEDULE - 23: INTEREST</b>		
a) On fixed loans	-	-
b) On other Loans (including Bank Charges)	-	-
c) Others (specify)	5,81,934	8,23,409
<b>TOTAL</b>	<b>5,81,934</b>	<b>8,23,409</b>



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE,  
BANGALORE**

(Registered under the Karnataka Societies' Registration Act)  
GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULE FORMING PART OF ANNUAL ACCOUNTS FOR THE PERIOD  
ENDED MARCH, 31, 2024**

**SCHEDULE 24 - SIGNIFICANT ACCOUNTING POLICIES**

1. ACCOUNTING CONVENTION

The Financial statements are prepared on the basis of historical cost convention.

2. INVESTMENTS

Investment are carried at cost. The decline in their value, which is other than temporary is provided for.

3. PROPERTY, PLANT & EQUIPMENT (PPE)

3.1 PPE are capitalized at cost of acquisition inclusive of inward freight, duties and taxes and incidental and direct expenses related to acquisition and it is carried in the balance sheet net of accumulated depreciation.

3.2 Cost of PPE acquired out of project funds are also taken as Assets by debiting the appropriate head of Fixed Assets of the Institute and by crediting corresponding amount to Capital Reserve. Every year Capital reserve is reversed to the extent of depreciation, calculated under the WDV method at the rates of depreciation prescribed under the Income Tax Rules, 1962. In the event of the asset being returned to the agency sanctioning the grant, the written down value will be adjusted by reversing the entries.

4. DEPRECIATION

4.1 Depreciation is provided on written down value method as per rates specified in the Income-tax Act, 1961.

4.2 Depreciation of assets commences when the assets are ready for their intended use which is generally on commissioning/installation. The total amount of depreciation on assets acquired out of Core and EMG funds for the year is transferred from Capital Reserve to Income and Expenditure Account.

5. GOVERNMENT GRANTS / SUBSIDIES

5.1 Grants received from the Government are of two types: (a) Non-Recurring Grants - which are for the purpose of acquiring Capital Assets. The amount of grants received is initially credited to Corpus / Capital fund account and expenditure incurred for acquisition of capital assets is debited thereto. The balance in this account represents the unspent amount of non-recurring grant. The amount equivalent to capital assets added during the year is added to capital reserve account. (b) Recurring Grants - which are for the purpose of recurring expenditure and are taken directly to Income & Expenditure Account. Unspent balance/excess of expenditure over income is shown in Reserves & Surplus Account distinctly under General Reserve. The combined balance in this account is the total unspent balance of grants.

5.2 Government grants / subsidy are accounted on receipt basis.





## 6. EARMARKED/ENDOWMENT FUNDS

- 6.1 Project Funding by both Government and non-government agencies to whom a statement of account of the expenditure incurred together with a utilization Certificate of the amount released has to be furnished are accounted under this heading. Fellowships/Scholarships sanctioned by UGC/CSIR and other agencies are also accounted under this head in order to watch the balance available/recoverable on each such award. Based on the conditions and limits stipulated in the sanction order, expenditure is incurred.
- 6.2 Such Earmarked/Endowment Funds towards specific projects, to the extent unspent is carried in the Balance Sheet as a liability under the head "Earmarked/Endowment Funds". Project-wise details of funds received and corresponding expenditure during the year is furnished along with opening and closing unspent balances of specific funds under Schedule 3. Upon Completion of the project in its entirety, the same is removed from the list in Schedule 3. When tangible Fixed Assets are acquired out of the projects funds, the appropriate head of Fixed Assets is debited with corresponding credit to Capital Reserve. Every year Capital reserve is reversed to the extent of depreciation, calculated under the WDV method at the rates of depreciation prescribed under the Income Tax Rules, 1962.

## 7. FOREIGN CURRENCY TRANSACTIONS

- 7.1 Transactions denominated in foreign currency are accounted at the exchange rate prevailing at the date of the transaction.
- 7.2 Current assets, foreign currency loans and current liabilities are converted at the exchange rate prevailing as at the year end. The resultant gain / loss is adjusted to cost of fixed assets, if the foreign currency liability relates to fixed assets, and in other cases is considered to revenue.

## 8. LEASE

Lease rentals are expensed with reference to lease terms.

## 9. RETIREMENT BENEFITS

- 9.1 The provision for leave encashment is provided based on the actuarial valuation. The Institute has a plan with Life Insurance Corporation of India who provides the actuarial valuation.
- 9.2 The provision for gratuity is provided based on the actuarial valuation. The Institute has a group gratuity plan with Life Insurance Corporation of India who provides the actuarial valuation.

## 10. REVENUE RECOGNITION

10.1 INCOME FROM FACILITY SERVICES: Income is derived from services in relation to usage of facilities available at the institute by external users and are billed at specified rate on accrual basis along with applicable GST.

10.2 INTEREST FROM BANKS: Interest earned is accounted on accrual basis as per bank statement.

10.3 MISC INCOME: Charges for internal usage of facilities at the institute for research purposes is accounted (net) under this head. As this is purely for internal purposes no GST is applicable.



**INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE,  
BANGALORE**

(Registered under the Karnataka Societies' Registration Act)  
GKVK, BELLARY ROAD, BANGALORE - 560 065

**SCHEDULE FORMING PART OF ANNUAL ACCOUNTS FOR THE PERIOD  
ENDED MARCH, 31, 2024**

**SCHEDULE 25 - CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS**

**1. CONTINGENT LIABILITIES**

**1.1 In respect of:**

- Bank guarantees given by / on behalf of the Entity - Rs. NIL /- (Previous year Rs. NIL/-)
- Letters of Credit opened by Bank on behalf of the Entity - Rs. NIL/- (Previous year Rs. NIL/-)
- Bills discounted with banks Rs. NIL/- (Previous year Rs. NIL/-)

**1.2 Disputed demands in respect of:**

- Income-tax Rs. NIL/- (Previous year Rs. NIL/-)
- Sales-tax Rs. NIL/- (Previous year Rs. NIL/-)
- Municipal Taxes Rs. NIL/- (Previous year Rs. NIL/-)

**1.3 In respect of claims from parties for non-execution of orders, but contested by the Entity - Rs. NIL/- (Previous year Rs. NIL/-)**

**1.4 NCBS-TIFR was the executing agency for the construction of inStem Building. Accordingly, NCBS - TIFR has issued work orders for Construction of Buildings for Laboratories & Associated facilities and one such work order was issued on M/s. URC Constructions in pre-GST regime.**

Against the said Work Order M/s. URC Construction have claimed amount towards GST at the rate of 18% which has been disputed by NCBS- TIFR based on circular No. SE/TAS/GST/04 from CPWD dated 22.09.2017. Currently the subject matter is under arbitration (A. C. No. 401 / 2022) and the decision of the arbitrator is yet to be pronounced. As per Executing Agency (NCBS - TIFR), the total claim of M/s. URC Construction is about Rs.3.48 Crores towards unpaid GST.

As on 31.03.2024, an advance amount of Rs.1.52 Crore is with NCBS.

**2. CAPITAL COMMITMENTS**

Estimated value of contracts remaining to be executed on capital account and not provided for Rs. 1.80 crores (Previous year Rs.NIL/-).



3. LEASE OBLIGATIONS

Future obligations for rentals under finance lease agreements for plant and machinery amount to Rs.NIL/- (Previous year Rs. NIL/-).

4. CURRENT ASSETS, LOANS AND ADVANCES

In the opinion of the Management, the current assets, loans and advances have a value on realization in the ordinary course of business, equal at least to the aggregate amount shown in the Balance Sheet.

5. TAXATION

The Society is registered under section 12A of the Income Tax Act, 1961 under the category Charitable Trust. The Society is filing the income tax return by claiming exemption under section 11 of the Income Tax Act, 1961.

6. FOREIGN CURRENCY TRANSACTIONS (Amount in Rs.)

6.1 Value of Imports Calculated on C.I.F. Basis:

Particulars	Current Year	Previous Year
Purchase of Finished Goods	NIL/-	NIL/-
Raw Material & Components (including in transit)	NIL/-	NIL/-
Capital Goods	0	7,35,67,362/-
Stores, Spares & Consumables	91,51,218	1,49,71,715/-

6.2 Expenditure in foreign currency:

Particulars	Current Year	Previous Year
Travel	29,26,095	NIL/-
Interest payment	NIL/-	NIL/-
Collaboration Expense	NIL/-	NIL/-
Remuneration	1,30,215	14,08,841/-
Publication charges & Training	27,15,348	25,57,084/-

6.3 Earnings:

Particulars	Current Year	Previous Year
Value of Exports	20,46,701	NIL



7. Remuneration to auditors

<b>Particulars</b>	<b>Amount(Rs.)</b>
As Statutory Auditors*	125,000/-
For Taxation Matters	NIL/-
For Certification	3,540/-

\* Audit fee for inStem and CSCR is Rs.85,000/- (exclusive of GST) and Rs.40,000/- (excluding GST) respectively.

8. The Institute, National Centre for Biological Sciences (NCBS), Tata Institute Genetics and Society and C-Camp are located in a common campus. As per the MOU entered into between the four(4) entities, common expenditure incurred by any institute is shared by other three entities. The Institute accounts these expenditures on the basis of the Debit Note raised by respective institutes.
9. Expenses are allocated between Core and EMG based on the scientific progress achieved in laboratories utilising common inputs.
10. Share Certificates of C-Camp are held in the name of persons employed in the BLiSC campus as representatives of the institute.
11. The Institute's Building and Infrastructure are located on Lease Hold Land. The lease deed is between The University of Agricultural Sciences (UAS) and Department of Bio-Technology, Ministry of Science and Technology (DBT) have entered into a Lease Deeds on 05-04-2008, 29-07-2008, 04-11-2009 and 15-11-2012 whereby the UAS has granted 20 acres of land on 49 years of lease to DBT for establishment of the Institute.
12. Corresponding figures for the previous year have been regrouped / rearranged, wherever necessary. ,
13. Schedules 1 to 25 are annexed to and from an integral part of the Balance Sheet as at March 31, 2024 and the Income and Expenditure Account for the year ended on that date.

*S. Srinivas*

